CSPC Pharmaceutical Group Ltd (CHJTF)
0.75
0.00 (0.00%)
USD |
OTCM |
Apr 22, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.922B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -24.24% |
| Valuation | |
| PE Ratio | 10.72 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.001 |
| Price to Book Value | 1.905 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0179 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0136 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 52.10% |
Profile
| CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series. |
| URL | https://www.cspc.com.hk |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Sep. 13, 2024 (est.) |
| Last Earnings Release | Mar. 20, 2024 |
| Next Ex-Dividend Date | May. 31, 2024 |
| Last Ex-Dividend Date | Sep. 07, 2023 |
Ratings
Profile
| CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series. |
| URL | https://www.cspc.com.hk |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Sep. 13, 2024 (est.) |
| Last Earnings Release | Mar. 20, 2024 |
| Next Ex-Dividend Date | May. 31, 2024 |
| Last Ex-Dividend Date | Sep. 07, 2023 |